Galapagos

Terratis, a French company, specializes in large-scale pest control using the Sterile Insect Technique (SIT). They focus on reducing populations of tiger mosquitoes and agricultural pests by releasing sterilized male insects, providing a chemical-free, environmentally sustainable solution for public health authorities and agricultural sectors.

Frontier Medicines Corporation, established in 2018 and headquartered in South San Francisco, California, is a pre-clinical stage biopharmaceutical company specializing in cancer research. The company employs chemoproteomics to discover and develop novel medicines targeting cancer-causing proteins. Frontier Medicines' innovative platform integrates advanced computational methods and machine learning algorithms to identify and pharmacologically target new binding pockets on proteins, thereby enabling small-molecule drug discovery and development for previously inaccessible targets.

CellPoint is dedicated to developing CAR-T therapies at the point of care, making these therapies more affordable and accessible to patients. CellPoint has developed a 6-day manufacturing process, powered by its proprietary xCellit real-time monitoring software system, that allows for 1 week of vein-to-vein time compared to over one month with current industrial manufacturing platforms.

Abound Bio, Inc. is a biotechnology company focused on developing innovative antibody-based biological therapeutics for cancer and infectious diseases. Founded in 2019 and located in Pittsburgh, Pennsylvania, the company has created extensive human antibody libraries that include diverse formats such as standard Fab, scFv, and unique VH domains. Abound Bio employs advanced techniques to rapidly identify high-affinity binders and can engineer these antibodies to enhance their drugability. The company specializes in producing candidate therapeutics suitable for various applications, including IgGs, multispecific antibodies, CARs, fusion proteins, and antibody-drug conjugates. Their research encompasses a comprehensive range of processes, including the development of novel scaffolds, phage-display libraries, and bioinformatics analysis, all aimed at addressing significant medical needs in their target fields.

VitalNext is a company that focuses on developing innovative life science technologies aimed at improving the health and well-being of the aging population. The company specializes in creating products with evidence-based health benefits, addressing the growing demand for solutions that support healthy aging as life expectancy increases. VitalNext's most advanced product is an innovative medical nutrition designed to improve body weight and muscle mass in malnourished individuals. These products are brought to market through distribution or licensing agreements with specialized business partners.

Cangenix provides a range of crystallographic and biophysical techniques, such as surface plasmon resonance (SPR) and isothermal titration calorimetry (ITC), using tailored biological reagents to accelerate the understanding of compound-target interactions and utilize structural, kinetic and thermodynamic data to inform drug design.

Argenta Discovery is a privately held contract research drug discovery company.

ProStrakan is a rapidly growing specialty pharmaceutical company engaged in the development and commercialisation of prescription medicines for the treatment of unmet therapeutic needs in major markets. With more than 300 people employed by the Company, ProStrakan is headquartered in Scotland with commercial operations throughout the rest of the UK and continental Europe and a US head office. The Company's Development group is located in Galashiels, Scotland and Bedminster, New Jersey, US.

Inpharmatica is a company specializing in predictive informatics for medicinal chemistry and ADME, aimed at enhancing the efficiency and productivity of drug discovery. Established in 1998, the company operates from its locations in London and Cambridge, employing approximately 35 professionals. Inpharmatica leverages its proprietary technologies to offer a comprehensive suite of discovery services, covering the entire research process from target identification to candidate selection. By utilizing natural materials for health, it provides unique insights and solutions that allow medicinal companies to explore the relationships between protein structure and function, facilitating the identification of drug targets for further development. Its integrated approach enables clients to access complete end-to-end technologies or select individual components tailored to their specific needs.

BioFocus DPI Ltd develops gene-to-candidate drug discovery products and provides services to biotech, pharma, and patient and non-profit organizations.